Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)
Author
Borrero-Palacios, A.; Cebrián, A.; Gómez del Pulgar, M. T.; García-Carbonero, R.; Garcia-Alfonso, P.; Aranda, E.; Elez, E.; López-López, R.; Cervantes, A.; Valladares, M.; Nadal, C.; Viéitez, J. M.; Guillén-Ponce, C.; Rodríguez, J.; Hernández, I.; García, J. L.; Vega-Bravo, R.; Puime-Otin, A.; Martínez-Useros, J.; Del Puerto-Nevado, L.; Rincón, R.; Rodríguez-Remírez, M.; Rojo, F.; García-Foncillas López, Jesús Miguel
Entity
UAM. Departamento de MedicinaPublisher
Nature Research (part of Springer Nature)Date
2019-05-17Citation
10.1038/s41598-019-43809-z
Scientific Reports 9 (2019): 7706
ISSN
2045-2322 (online)DOI
10.1038/s41598-019-43809-zEditor's Version
https://doi.org/10.1038/s41598-019-43809-zSubjects
KIR2DS4; Cetuximab; Metastatic colorectal cancer; Polymorphism FcγRIIIa V158F; Combination; MedicinaRights
© The Author(s) 2019Abstract
The original version of this Article contained an error in the spelling of the author P. Garcia-Alfonso, which was incorrectly given as P. Garcia. This error has now been corrected in the PDF and HTML versions of this Article.
Files in this item
Google Scholar:Borrero-Palacios, A.
-
Cebrián, A.
-
Gómez del Pulgar, M. T.
-
García-Carbonero, R.
-
Garcia-Alfonso, P.
-
Aranda, E.
-
Elez, E.
-
López-López, R.
-
Cervantes, A.
-
Valladares, M.
-
Nadal, C.
-
Viéitez, J. M.
-
Guillén-Ponce, C.
-
Rodríguez, J.
-
Hernández, I.
-
García, J. L.
-
Vega-Bravo, R.
-
Puime-Otin, A.
-
Martínez-Useros, J.
-
Del Puerto-Nevado, L.
-
Rincón, R.
-
Rodríguez-Remírez, M.
-
Rojo, F.
-
García-Foncillas López, Jesús Miguel
-
Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD)
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer
Borrero-Palacios, A.; Cebrián, A.; Gómez del Pulgar, M. T.; García-Carbonero, R.; García, P.; Aranda, E.; Elez, E.; López-López, R.; Cervantes, A.; Valladares, M.; Nadal, C.; Viéitez, J. M.; Guillén-Ponce, C.; Rodríguez, J.; Hernández, I.; García, J. L.; Vega-Bravo, R.; Puime-Otin, A.; Martínez-Useros, J.; Del Puerto-Nevado, L.; Rincón, R.; Rodríguez-Remírez, M.; Rojo, F.; García-Foncillas López, Jesús Miguel
2019-02-22 -
UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept
Martínez-Useros, Javier; Georgiev-Hristov, Tihomir; Fernández-Aceñero, María Jesús; Borrero-Palacios, Aurea; Indacochea, Alberto; Guerrero, Santiago; Li, Weiyao; Cebrián, Arancha; Gómez del Pulgar, Teresa; Puime-Otin, Alberto; Puerto-Nevado, Laura del; Rodríguez-Remírez, María; Pérez, Nuria; Celdrán, Angel; Gebauer, Fátima; García-Foncillas López, Jesús Miguel
2017-08-01